Novabridge Biosciences ADR (NBP)

$2.05 -0.01 (-0.49%)
Market Cap 242.86M
Revenue (ttm) 0.00
Net Income (ttm) -46.27M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,579,989
Avg Vol 1,033,288
Day's Range N/A - N/A
Shares Out 115.65M
Stochastic %K 7%
Beta 1.56
Analysts Strong Sell
Price Target $8.25

Company Profile

NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Ce...

Industry: Biotechnology
Sector: Healthcare
Phone: 240 745 6330
Address:
2440 Research Boulevard, Suite 400, Rockville, United States
Latest News on NBP
NovaBridge to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference

May 12, 2026, 7:00 AM EDT - 1 day ago

NovaBridge to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference

NovaBridge Appoints Mark Hagler as President and Chief Commercial Officer to Advance Commercial Strategy and Maximize Pipeline Value

Apr 22, 2026, 7:00 AM EDT - 21 days ago

NovaBridge Appoints Mark Hagler as President and Chief Commercial Officer to Advance Commercial Strategy and Maximize Pipeline Value

NovaBridge Reports Full Year 2025 Financial Results and Provides Business Update

Apr 7, 2026, 4:50 PM EDT - 5 weeks ago

NovaBridge Reports Full Year 2025 Financial Results and Provides Business Update

NovaBridge had ‘productive’ FDA meeting on potential gastric cancer treatment

2026-03-16T11:11:19.000Z - 2 months ago

NovaBridge had ‘productive’ FDA meeting on potential gastric cancer treatment

NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer

Mar 16, 2026, 7:00 AM EDT - 2 months ago

NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer

NovaBridge Biosciences Transcript: Leerink Global Healthcare Conference 2026

Mar 11, 2026, 8:00 AM EDT - 2 months ago

NovaBridge Biosciences Transcript: Leerink Global Healthcare Conference 2026

NovaBridge Biosciences Transcript: Status update

Mar 9, 2026, 9:00 AM EDT - 2 months ago

NovaBridge Biosciences Transcript: Status update

NovaBridge, Visara announce results from VIS-101 Phase 2a Wet AMD study

2026-03-09T11:20:50.000Z - 2 months ago

NovaBridge, Visara announce results from VIS-101 Phase 2a Wet AMD study

NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study

Mar 9, 2026, 7:00 AM EDT - 2 months ago

NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study

NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026

Mar 3, 2026, 9:05 AM EST - 2 months ago

NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026

NovaBridge to Present at the Leerink Partners 2026 Global Healthcare Conference

Mar 2, 2026, 7:00 AM EST - 2 months ago

NovaBridge to Present at the Leerink Partners 2026 Global Healthcare Conference

NovaBridge appoints Cunningham as Vice Chairman of Board of Directors

2026-02-19T12:39:10.000Z - 2 months ago

NovaBridge appoints Cunningham as Vice Chairman of Board of Directors

NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform

Feb 19, 2026, 7:00 AM EST - 2 months ago

NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform

NovaBridge enrolls first patient in givastomig combination study

2026-02-17T21:45:16.000Z - 3 months ago

NovaBridge enrolls first patient in givastomig combination study

NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric Cancer

Feb 17, 2026, 4:05 PM EST - 3 months ago

NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric Cancer

NovaBridge resumed with a Buy at H.C. Wainwright

2026-02-06T11:12:13.000Z - 3 months ago

NovaBridge resumed with a Buy at H.C. Wainwright

NovaBridge announces open market purchases by executive chairman Fu Wei

2026-01-20T12:15:28.000Z - 4 months ago

NovaBridge announces open market purchases by executive chairman Fu Wei

NovaBridge Announces Open Market Purchases by Executive Chairman, Fu Wei

Jan 20, 2026, 7:00 AM EST - 4 months ago

NovaBridge Announces Open Market Purchases by Executive Chairman, Fu Wei

NovaBridge presents dose expansion data from Phase 1b study of givastomig

2026-01-06T12:22:11.000Z - 4 months ago

NovaBridge presents dose expansion data from Phase 1b study of givastomig

NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer

Jan 6, 2026, 7:00 AM EST - 4 months ago

NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer

NovaBridge to Ring the Nasdaq Opening Bell on Friday, January 2, 2026

Dec 30, 2025, 7:00 AM EST - 4 months ago

NovaBridge to Ring the Nasdaq Opening Bell on Friday, January 2, 2026

NovaBridge’s ragistomig shows anti-tumor efficacy in Phase 1 trial

2025-12-10T21:40:38.000Z - 5 months ago

NovaBridge’s ragistomig shows anti-tumor efficacy in Phase 1 trial

NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO

Dec 10, 2025, 4:30 PM EST - 5 months ago

NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO

NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO

Dec 3, 2025, 7:30 PM EST - 5 months ago

NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO

NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward

Nov 20, 2025, 8:00 PM EST - 6 months ago

NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward

NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries

Oct 29, 2025, 6:27 PM EDT - 7 months ago

NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries

I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform

Oct 29, 2025, 9:00 AM EDT - 7 months ago

I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform

I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025

Oct 22, 2025, 12:35 PM EDT - 7 months ago

I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025

NovaBridge Biosciences Transcript: Investor Update

Oct 16, 2025, 4:45 PM EDT - 7 months ago

NovaBridge Biosciences Transcript: Investor Update

I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences

Oct 16, 2025, 4:05 PM EDT - 7 months ago

I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences

I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

Oct 14, 2025, 7:00 AM EDT - 7 months ago

I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

NovaBridge Biosciences Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 10, 2025, 9:30 AM EDT - 8 months ago

NovaBridge Biosciences Transcript: H.C. Wainwright 27th Annual Global Investment Conference

I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee

Aug 25, 2025, 7:00 AM EDT - 9 months ago

I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee

I-Mab to Participate in September Investor Conferences

Aug 21, 2025, 7:00 AM EDT - 9 months ago

I-Mab to Participate in September Investor Conferences

Everest Medicines Expands Strategic Investment in I-MAB

Aug 1, 2025, 8:56 AM EDT - 10 months ago

Everest Medicines Expands Strategic Investment in I-MAB

I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares

Aug 1, 2025, 8:00 AM EDT - 10 months ago

I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares

I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health

Jul 17, 2025, 7:00 AM EDT - 10 months ago

I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health

NovaBridge Biosciences Transcript: Status Update

Jul 8, 2025, 2:00 PM EDT - 11 months ago

NovaBridge Biosciences Transcript: Status Update

I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

Jul 2, 2025, 11:15 AM EDT - 11 months ago

I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research

Jun 30, 2025, 4:01 PM EDT - 11 months ago

I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research

I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

Jun 26, 2025, 6:30 AM EDT - 11 months ago

I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

NovaBridge Biosciences Transcript: H.C. Wainwright “HCW@Home” series

Jun 17, 2025, 10:00 AM EDT - 11 months ago

NovaBridge Biosciences Transcript: H.C. Wainwright “HCW@Home” series

NovaBridge Biosciences Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 3:45 PM EDT - 1 year ago

NovaBridge Biosciences Transcript: Jefferies Global Healthcare Conference 2025

I-Mab to Present at Jefferies Global Healthcare Conference

May 20, 2025, 7:00 AM EDT - 1 year ago

I-Mab to Present at Jefferies Global Healthcare Conference

NovaBridge Biosciences Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 7, 2025, 8:45 AM EDT - 1 year ago

NovaBridge Biosciences Transcript: 24th Annual Needham Virtual Healthcare Conference

I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Mar 21, 2025, 4:30 PM EDT - 1 year ago

I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

I-Mab Announces Accelerated Givastomig Phase 1b Study Progress

Mar 7, 2025, 7:00 AM EST - 1 year ago

I-Mab Announces Accelerated Givastomig Phase 1b Study Progress

I-Mab to Participate in Leerink Partners Global Healthcare Conference

Feb 18, 2025, 7:00 AM EST - 1 year ago

I-Mab to Participate in Leerink Partners Global Healthcare Conference

NovaBridge Biosciences Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Feb 11, 2025, 4:00 PM EST - 1 year ago

NovaBridge Biosciences Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

I-Mab to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 7:30 AM EST - 1 year ago

I-Mab to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member

Jan 8, 2025, 7:00 AM EST - 1 year ago

I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member

I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program

Jan 6, 2025, 7:00 AM EST - 1 year ago

I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program

NovaBridge Biosciences Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 4, 2024, 4:30 PM EST - 1 year ago

NovaBridge Biosciences Transcript: Piper Sandler 36th Annual Healthcare Conference

I-Mab to Participate at the Piper Sandler Healthcare Conference

Nov 21, 2024, 7:00 AM EST - 1 year ago

I-Mab to Participate at the Piper Sandler Healthcare Conference

I-Mab Reports Third Quarter 2024 Results

Nov 14, 2024, 7:00 AM EST - 1 year ago

I-Mab Reports Third Quarter 2024 Results

I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer

Nov 6, 2024, 7:00 AM EST - 1 year ago

I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer

I-Mab to Release Q3 2024 Financial Results on November 14, 2024

Oct 31, 2024, 7:00 AM EDT - 1 year ago

I-Mab to Release Q3 2024 Financial Results on November 14, 2024

I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024

Oct 30, 2024, 7:00 AM EDT - 1 year ago

I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024

I-Mab to Participate at the Truist Securities BioPharma Symposium

Oct 28, 2024, 7:00 AM EDT - 1 year ago

I-Mab to Participate at the Truist Securities BioPharma Symposium

I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024

Sep 16, 2024, 4:01 PM EDT - 1 year ago

I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024

I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer

Sep 10, 2024, 7:00 AM EDT - 1 year ago

I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer

NovaBridge Biosciences Earnings Call Transcript: H1 2024

Aug 28, 2024, 8:00 AM EDT - 1 year ago

NovaBridge Biosciences Earnings Call Transcript: H1 2024

I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates

Aug 28, 2024, 7:00 AM EDT - 1 year ago

I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates

I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 26, 2024, 7:00 AM EDT - 1 year ago

I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

I-Mab to Release 1H 2024 Financial Results on August 28, 2024

Aug 14, 2024, 7:00 AM EDT - 1 year ago

I-Mab to Release 1H 2024 Financial Results on August 28, 2024

I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC)

Aug 7, 2024, 7:00 AM EDT - 1 year ago

I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC)

I-Mab Announces Leadership Transitions

Jul 15, 2024, 7:30 AM EDT - 1 year ago

I-Mab Announces Leadership Transitions

I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers

Jun 5, 2024, 7:00 AM EDT - 2 years ago

I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers

BMY